Navigation Links
Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis
Date:7/29/2009

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new six month safety and efficacy results from its fourth Phase II clinical trial using its proprietary, orally-active non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. Consistent with previously reported six month (Petal Study) and three month (Lilac Petal Study) results, a favorable safety profile and clinically meaningful efficacy have again been confirmed through month six of the Lilac Petal Study. This newly available data also provides clinical confirmation of Neurocrine's extensive pharmacologic modeling related to the elagolix dose-response continuum. The outcome of primary interest at month six was the impact of the elagolix 250 mg dose on bone mineral density (BMD) as measured by dual energy X-ray absorptiometry (DXA) scanning.

Over the six month treatment period, elagolix 150 mg once daily had minimal impact on BMD (-0.80% mean change from baseline, femur; -0.66% mean change from baseline, spine). The 250 mg once daily dose, as expected, had slightly greater percentage change from baseline at month six (-1.0% femur, -1.6% spine). The 150 mg once daily BMD profile in this Lilac Petal Study is consistent with that previously demonstrated in the six-month Petal Study.

"We selected the 150 mg and 250 mg once daily doses for this study based upon predictions generated from extensive modeling of dose, estradiol and bone mineral density relationships. Prior to this study we anticipated that the 250 mg dose would provide exposure such that we would start to see an increased impact on bone mineral density in a small portion of study subjects. The Lilac Petal data confirm that our modeling of the dose-response curve was accurate," said C
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
2. Blue Marble Energy Corp. Announces Successful Close of Series A Financing
3. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
4. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
5. Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UKs Veterinary Laboratories Agency
6. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
7. Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
8. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
9. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
10. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
11. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Research and Markets  has announced the addition of ... Geography - Global Analysis and Forecast (2014 - 2020)" ... electronics, also called as polymer electronics or plastic electronics, ... small conductive molecules and electrically conductive polymers. It is ... carbon based, made using synthetic strategies developed in the ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
(Date:10/20/2014)... 20, 2014  GenVec, Inc. (NASDAQ: GNVC ) ... Ph.D., from its board of directors effective on October 24, ... and served as its chairman from June 2006 to November ... and Corporate Governance and Audit Committees of the board.  ... decade of dedicated service to GenVec, and its stockholders," said ...
(Date:10/20/2014)... OR (PRWEB) October 20, 2014 Local ... participate in an investigational study of donor stem cells ... in stem cell therapy and has performed clinical stem ... this study is to determine if a single injection ... affected joints can help reduce pain and inflammation in ...
Breaking Biology Technology:Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... funded by the Biotechnology and Biological Sciences Research Council (BBSRC), ... new type of vaccine to protect chickens against coccidiosis, the ... of this type -- based on proteins from the coccidiosis ... could be produced on a larger scale than is currently ...
... of researchers has invented new artificial muscles strong enough to ... the same flexibility of an elephant,s trunk or octopus limbs. ... Express, the scientists and engineers from the University of ... of Texas at Dallas and Hanyang University in Korea detail ...
... MANSFIELD, Mass., Oct. 13, 2011 PrimeraDx today announced ... President of Corporate Development.   "Jeff,s diverse ... a great addition to the leadership team," Said Matt ... leverage the multimodal capabilities of the ICE Plex ...
Cached Biology Technology:A step towards new vaccines for most important chicken parasite 2A step towards new vaccines for most important chicken parasite 3UBC researchers invent tiny artificial muscles with the strength, flexibility of elephant trunk 2PrimeraDx Appoints Jeff Liter as VP of Corporate Development 2
(Date:10/16/2014)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market announces ... the Smart Wallet, at the 13 th annual ... global conference on the intersection of technology and the ... , founder and publisher of the Strategic News Service™, ...
(Date:10/15/2014)... spreading rapidly and to an unexpected extent. The outbreak ... and the virus shows a new disease dynamic in ... this reason, the German National Academy of Sciences Leopoldina, ... and the Union of the German Academies of Sciences ... epidemic today. , In the statement the academies call ...
(Date:10/14/2014)... thieves, prostate cancer tumors scavenge and hoard copper that ... avarice may be a fatal weakness. , Researchers ... prostate cancer cells by delivering a trove of copper ... cells brimming with the mineral, leaving non-cancer cells healthy. ... commercially available for other uses, could soon be tested ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2
... , April 27 Tyco International Ltd. (NYSE: ... of its Electrical & Metal Products business. Tyco expects to file documents ... months and to complete the proposed transaction in the first half of ... traded U.S. company. , , ...
... , April 27 The Breema Center today ... Germany the 12-16 of May, 2010. Breema is a ... emphasizes the mind-body connection.  The Intensive program is designed to ... long time students deepen their understanding of Breema and its ...
... Debt advice specialists at MoneySolve believe that the record level of personal ... of financial management and debt education. , ... More than 134,000 people became insolvent during 2009, by entering ... to experience severe financial difficulties. Experts at MoneySolve believe that by increasing ...
Cached Biology News:Tyco International To Pursue Spin-Off of Electrical & Metal Products Business 2Tyco International To Pursue Spin-Off of Electrical & Metal Products Business 3Breema Center to Host International Intensive Week in Buhl, Germany 2Breema Center to Host International Intensive Week in Buhl, Germany 3
... Note: Protein determined by Biuret Physical form: ... Tris-HCl, pH 7.6, 1 mM MgCl 2 ... Preparation Unit Definition: One unit will hydrolyze ... at pH 9.8 at 37 C. • ...
... Varioskan is a high performance ... dispenser and incubator. With the advanced ... and reliability for drug discovery assay ... for fluorescence intensity, time-resolved fluorescence and ...
Immulon 2 HB 1x8 Strip assembled, C-bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
... RCT series of refrigerated cold traps offers ... of low volatility/aqueous solvents or high volatility ... other vacuum concentrators/centrifugal evaporators. Also used for ... such as used in electron microscopes. Can ...
Biology Products: